ImmunoPrecise Antibodies Ltd. Files Form 6-K
Ticker: HYFT · Form: 6-K · Filed: Oct 11, 2024 · CIK: 1715925
Sentiment: neutral
Topics: 6-K, corporate-filing, shareholder-meeting
TL;DR
IPA files 6-K, includes notice for shareholder meeting. CFO Kristin Taylor signed off.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 11, 2024, reporting for the month of October 2024. The filing includes an Amended Notice of Annual General and Special Meeting as Exhibit 99.1. Kristin Taylor, Chief Financial Officer, signed the report on behalf of the company.
Why It Matters
This filing indicates ongoing corporate activities and regulatory compliance for ImmunoPrecise Antibodies Ltd., including the scheduling of an important shareholder meeting.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Chief Financial Officer
- October 11, 2024 (date) — Filing Date
- 001-39530 (other) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed by ImmunoPrecise Antibodies Ltd. for the month of October 2024, to report information to the SEC.
What is included as an exhibit in this filing?
Exhibit 99.1, an Amended Notice of Annual General and Special Meeting, is included in this filing.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor, Chief Financial Officer, signed the report on behalf of ImmunoPrecise Antibodies Ltd.
When was this report filed with the SEC?
This report was filed with the SEC on October 11, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Filing Stats: 163 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-10-11 15:25:08
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 8KB
- exhibit99-1x1x1.jpg (GRAPHIC) — 3KB
- 0001062993-24-017616.txt ( ) — 17KB
From the Filing
ImmunoPrecise Antibodies Ltd.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 . Commission File Number: 001-39530 ImmunoPrecise Antibodies Ltd. (Exact Name of Registrant as Specified in Charter) 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 11, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer EXHIBIT INDEX 99.1 Amended Notice of Annual General and Special Meeting dated October 10, 2024